Arashdeep Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arashdeep Singh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Mishra
Command Hospital (Northern Comd), Udhampur, India
1 shared publication - Abhishek Pathak
Department of Medical Oncology, Command Hospital, Lucknow, Uttar Pradesh, India
1 shared publication - Amol Patel
Indian Naval Hospital Ship Asvini (INHS Asvini), Mumbai, India
1 shared publication Arti Sarin
Western Naval Command, Mumbai, Maharashtra, India
1 shared publicationBabitha Pv
Day Care Chemotherapy Centre, INHS, Asvini, Mumbai, Maharashtra, India
1 shared publication- Bhavna Hooda
Department of Anaesthesiology and Critical Care, Army Hospital (R and R), New Delhi, India
1 shared publication
Latest Publications
- 28 March 2025
- Published by SAGE Publications in Journal of Perioperative Practice
- Vol. 35 (12) , 645-650
Effects of prone positioning on cerebral oxygenation in patients undergoing spine surgery under general anaesthesia
Background: Under general anaesthesia, the impact of body positioning on different organs is mostly determined by the subsequent changes in the cardiovascular system, which are monitored with standard monitors. However, there is no objective method of neuromonitoring, therefore impacts on brain homeostasis are mainly conjectural. Near-infrared spectroscopy is a non-invasive method for monitoring tissue cerebral oxygenation. In this study, we aimed to observe the effects of the prone position on cerebral oxygenation in patients under general anaesthesia. Methods: The study involved 44 patients undergoing spine surgeries in a prone position under general anaesthesia. Regional oxygen saturation readings were initially taken in the supine position and monitored continuously after transitioning to the prone position. A decrease in regional oxygen saturation of more than 20% was considered clinically significant. Results: A significant drop in blood pressure (p = 0.02) and heart rate (p = 0.04) was observed after positioning patients prone under general anaesthesia. In addition, end-tidal carbon dioxide levels rose notably after 30 min in the prone position (p = 0.017). Importantly, while no significant differences were found in cerebral oxygenation between the supine and prone positions, one patient did experience right-sided vision loss postoperatively. Conclusion: Using near-infrared spectroscopy monitors is recommended for patients with comorbidities and those undergoing surgeries with extended durations in the prone position.
- 28 March 2025
- Published by SAGE Publications in Journal of Perioperative Practice
- Vol. 35 (12) , 645-650
Effects of prone positioning on cerebral oxygenation in patients undergoing spine surgery under general anaesthesia
Background: Under general anaesthesia, the impact of body positioning on different organs is mostly determined by the subsequent changes in the cardiovascular system, which are monitored with standard monitors. However, there is no objective method of neuromonitoring, therefore impacts on brain homeostasis are mainly conjectural. Near-infrared spectroscopy is a non-invasive method for monitoring tissue cerebral oxygenation. In this study, we aimed to observe the effects of the prone position on cerebral oxygenation in patients under general anaesthesia. Methods: The study involved 44 patients undergoing spine surgeries in a prone position under general anaesthesia. Regional oxygen saturation readings were initially taken in the supine position and monitored continuously after transitioning to the prone position. A decrease in regional oxygen saturation of more than 20% was considered clinically significant. Results: A significant drop in blood pressure (p = 0.02) and heart rate (p = 0.04) was observed after positioning patients prone under general anaesthesia. In addition, end-tidal carbon dioxide levels rose notably after 30 min in the prone position (p = 0.017). Importantly, while no significant differences were found in cerebral oxygenation between the supine and prone positions, one patient did experience right-sided vision loss postoperatively. Conclusion: Using near-infrared spectroscopy monitors is recommended for patients with comorbidities and those undergoing surgeries with extended durations in the prone position.
- 10 December 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (12) , e261306
Pulmonary thromboembolism masquerading as bronchial asthma in a remote medical setup at extreme high altitude
Pulmonary thromboembolism (PTE) is a life-threatening illness. It is a great masquerader that mimics many respiratory illnesses, warranting a high index of suspicion for diagnosis. It should be suspected when respiratory illnesses do not respond to the expected course of treatment. At this point, additional imaging modalities such as echocardiography and CT scans can assist with the diagnosis; however, these facilities are usually not available in remote medical setups such as mountainous regions in the Himalayas. The definitive diagnosis is delayed until the patient is brought down to a well-equipped hospital at a lower altitude. Making an early provisional diagnosis is hence crucial for timely evacuation and optimal first-line management to circumvent associated morbidity and mortality. We present a case of PTE in a remote medical establishment whose initial evaluation pointed towards an episode of severe asthma. The poor response to standard management prompted us to undertake bedside echocardiography to diagnose features of PTE.
- 10 December 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (12) , e261306
Pulmonary thromboembolism masquerading as bronchial asthma in a remote medical setup at extreme high altitude
Pulmonary thromboembolism (PTE) is a life-threatening illness. It is a great masquerader that mimics many respiratory illnesses, warranting a high index of suspicion for diagnosis. It should be suspected when respiratory illnesses do not respond to the expected course of treatment. At this point, additional imaging modalities such as echocardiography and CT scans can assist with the diagnosis; however, these facilities are usually not available in remote medical setups such as mountainous regions in the Himalayas. The definitive diagnosis is delayed until the patient is brought down to a well-equipped hospital at a lower altitude. Making an early provisional diagnosis is hence crucial for timely evacuation and optimal first-line management to circumvent associated morbidity and mortality. We present a case of PTE in a remote medical establishment whose initial evaluation pointed towards an episode of severe asthma. The poor response to standard management prompted us to undertake bedside echocardiography to diagnose features of PTE.
- Open Access
- 1 July 2023
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 12 (03) , 238-244
Phase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols
Background Peg-GCSF has similar efficacy at a dose of 60 µg/kg and 100 µg/kg. The conventional 6 mg SC dose was based on the maximum tolerable dose. In Japan, 3.6 mg dose was approved on the basis of dose finding studies. Peg-GCSF is an integral part of dose-dense chemotherapy protocols. Dose finding and scheduling study of peg-GCSF have not been conducted in Indian patients. Materials and Methods We conducted two-center phase 1/2 clinical study addressing the timing and efficacy of peg-GCSF in Indian breast cancer patients (CTRI no: 2021/07/034751). Three groups of timing administration were studied, namely 1, 6, and 24 hours post chemotherapy. The phase 2 part was the expansion of the best timing group. The primary objective was dose density, which was defined as receiving chemotherapy on < 3 days of scheduled date. Adriamycin/epirubicin cyclophosphamide (AC/EC) was administered q2 weeks. The total leucocyte (TLC) and absolute neutrophil (ANC) kinetics were studied. Other outcomes were incidence of grade 4 neutropenia, febrile neutropenia (FN), and requirement of additional doses of G-CSF. Bone pain, fever, and myalgia were studied for adverse effects. Results From November 20 to December 21, 36 patients were enrolled. Patient characteristics are depicted in Table 1. Initially, three patients received the peg-GCSF in each timing group. One patient in each 1-hour and 6 hours needed G-CSF support for maintaining the dose density. The 24-hour group was carried to phase 2 part. Dose density was maintained in 97% of patients. None of the patient in 24-hour group had FN. Also, 4/30 patients had grade 4 neutropenia and required an additional dose of GCSF. Grade 3 or 4 bone pain was not noticed by any of the patients. During the first cycle, the mean ANC (cells/μL) was 5284, 20704, 3010, 6954 on D0, D + 3, D + 7, and D + 13, respectively (Fig. 1A-TLC and 1B-ANC). The mean ANC (cells/μL) rise on D + 3 in cycles 1, 2, 3, 4 was 23810, 29209, 32428,22455, respectively. Conclusion Dose density of AC/EC breast cancer protocol is maintained with peg-GCSF 3 mg. Post chemotherapy 24-hour timing of peg-GCSF administration remains as the standard. A phase 3 trial of 6 mg versus 3 mg is warranted.
- 1 July 2023
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 12 (03) , 238-244
Open AccessPhase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols
Background Peg-GCSF has similar efficacy at a dose of 60 µg/kg and 100 µg/kg. The conventional 6 mg SC dose was based on the maximum tolerable dose. In Japan, 3.6 mg dose was approved on the basis of dose finding studies. Peg-GCSF is an integral part of dose-dense chemotherapy protocols. Dose finding and scheduling study of peg-GCSF have not been conducted in Indian patients. Materials and Methods We conducted two-center phase 1/2 clinical study addressing the timing and efficacy of peg-GCSF in Indian breast cancer patients (CTRI no: 2021/07/034751). Three groups of timing administration were studied, namely 1, 6, and 24 hours post chemotherapy. The phase 2 part was the expansion of the best timing group. The primary objective was dose density, which was defined as receiving chemotherapy on < 3 days of scheduled date. Adriamycin/epirubicin cyclophosphamide (AC/EC) was administered q2 weeks. The total leucocyte (TLC) and absolute neutrophil (ANC) kinetics were studied. Other outcomes were incidence of grade 4 neutropenia, febrile neutropenia (FN), and requirement of additional doses of G-CSF. Bone pain, fever, and myalgia were studied for adverse effects. Results From November 20 to December 21, 36 patients were enrolled. Patient characteristics are depicted in Table 1. Initially, three patients received the peg-GCSF in each timing group. One patient in each 1-hour and 6 hours needed G-CSF support for maintaining the dose density. The 24-hour group was carried to phase 2 part. Dose density was maintained in 97% of patients. None of the patient in 24-hour group had FN. Also, 4/30 patients had grade 4 neutropenia and required an additional dose of GCSF. Grade 3 or 4 bone pain was not noticed by any of the patients. During the first cycle, the mean ANC (cells/μL) was 5284, 20704, 3010, 6954 on D0, D + 3, D + 7, and D + 13, respectively (Fig. 1A-TLC and 1B-ANC). The mean ANC (cells/μL) rise on D + 3 in cycles 1, 2, 3, 4 was 23810, 29209, 32428,22455, respectively. Conclusion Dose density of AC/EC breast cancer protocol is maintained with peg-GCSF 3 mg. Post chemotherapy 24-hour timing of peg-GCSF administration remains as the standard. A phase 3 trial of 6 mg versus 3 mg is warranted.